| Download | - View final version: Optimal expression, function, and immunogenicity of an HIV-1 vaccine derived from the approved Ebola vaccine, rVSV-ZEBOV (PDF, 4.5 MiB)
- View supplementary information: Optimal expression, function, and immunogenicity of an HIV-1 vaccine derived from the approved Ebola vaccine, rVSV-ZEBOV (PDF, 208 KiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.3390/vaccines11050977 |
|---|
| Author | Search for: Azizi, Hiva1; Search for: Knapp, Jason P.ORCID identifier: https://orcid.org/0000-0003-2147-6000; Search for: Li, Yue; Search for: Berger, Alice; Search for: Lafrance, Marc-AlexandreORCID identifier: https://orcid.org/0000-0002-6680-5691; Search for: Pedersen, Jannie; Search for: de la Vega, Marc-Antoine; Search for: Racine, TrinaORCID identifier: https://orcid.org/0000-0001-6370-8661; Search for: Kang, Chil-Yong; Search for: Mann, Jamie F. S.; Search for: Dikeakos, Jimmy D.; Search for: Kobinger, Gary; Search for: Arts, Eric J. |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
|
|---|
| Funder | Search for: National Institutes of Health; Search for: Canadian Institutes of Health Research; Search for: Canada Research Chair; Search for: Canada Foundation for Innovation |
|---|
| Format | Text, Article |
|---|
| Subject | human immunodeficiency virus type 1 (HIV-1); vesicular stomatitis virus (VSV) vector; HIV-1 Envelope glycoprotein; Ebola virus glycoprotein |
|---|
| Abstract | Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 results in high expression on the approved Ebola vaccine, rVSV-ZEBOV, also harboring the Ebola Virus (EBOV) glycoprotein (GP). Codon-optimized (CO) Env chimeras derived from a subtype A primary isolate (A74) are capable of entering a CD4+/CCR5+ cell line, inhibited by HIV-1 neutralizing antibodies PGT121, VRC01, and the drug, Maraviroc. The immunization of mice with the rVSV-ZEBOV carrying the CO A74 Env chimeras results in anti-Env antibody levels as well as neutralizing antibodies 200-fold higher than with the NL4-3 Env-based construct. The novel, functional, and immunogenic chimeras of CO A74 Env with the SIV_Env-TMCT within the rVSV-ZEBOV vaccine are now being tested in non-human primates. |
|---|
| Publication date | 2023-05-12 |
|---|
| Publisher | MDPI |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 65bf7e51-439f-47b4-92e2-43dcbaf415b9 |
|---|
| Record created | 2023-08-15 |
|---|
| Record modified | 2023-08-15 |
|---|
